

Estonia Pharmaceutical Market Report and Forecast 2025-2034

Market Report | 2025-06-25 | 250 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$2789.00
- Five User License \$3909.00
- Corporate License \$5099.00

Report description:

The Estonia pharmaceutical market was valued at USD 525.82 Million in 2024, driven by the rising incidence of chronic diseases and government initiatives across the region. The market is anticipated to grow at a CAGR of 6.55% during the forecast period of 2025-2034, with the values likely to reach USD 991.68 Million by 2034.

Estonia Pharmaceutical Market Overview

The pharmaceutical industry involves the development, production, and marketing of medications that improve health outcomes. It spans a wide range of therapeutic areas, including oncology, immunology, cardiology, and infectious diseases. Pharmaceutical companies conduct extensive research and clinical trials to create safe, effective drugs. This sector plays a crucial role in advancing global healthcare and combating diseases.

Estonia Pharmaceutical Market Growth Drivers

Expansion of Cross-Border E-Prescription Services Boosting Market Growth

The growing integration of digital health services and cross-border collaborations is driving the market. For instance, in September 2024, Estonia expanded its cross-border e-prescription service to include Lithuania and Latvia. This allows Estonian residents to easily obtain medications in Lithuanian pharmacies using their Estonian-issued e-prescriptions. The cross-border service will enhance patient access to essential medicines, supporting pharmaceutical market growth by improving accessibility, convenience, and efficiency in medication procurement across the Baltic region. This development is expected to positively impact Estonia's pharmaceutical market in the forecast period by increasing patient satisfaction and demand for e-prescription services.

Adoption of Advanced Technologies to Boost Estonia Pharmaceutical Market Value

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The rapid growth of deep-tech companies and increased investment in biotechnology are key drivers for Estonia's pharmaceutical market. For instance, in November 2024, GeneCode, an Estonian pharmaceutical development company, joined the European Innovation Council's Scaling Club. This membership will provide GeneCode with strategic mentorship, investment opportunities, and partnerships to advance its innovative drug development for neurodegenerative diseases. GeneCode's rising prominence in biotechnology, particularly in treatments for conditions like Parkinson's disease, strengthens Estonia's position in the global pharmaceutical landscape. The collaboration is expected to accelerate GeneCode's growth and further boost Estonia's pharmaceutical market, attracting investment and fostering innovation in the industry.

Estonia Pharmaceutical Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Surge in Generic Drug Usage to Propel Market Growth

The increasing adoption of generic drugs in Estonia, driven by cost-efficiency and improved accessibility, is transforming the pharmaceutical market. This trend is expected to fuel market growth, reducing healthcare costs while maintaining effective treatment options for patients.

Rising Prevalence of Diabetes and Cardiovascular Diseases Drives the Estonia Pharmaceutical Market Growth

With rising rates of diabetes and cardiovascular diseases in Estonia, the demand for related pharmaceutical treatments is growing. This trend is contributing to market development, prompting pharmaceutical companies to focus on innovations and expanding their portfolios to address these health concerns.

Adoption of Digital Health Solutions to Boost the Estonia Pharmaceutical Market Value

The growing emphasis on digital health technologies, including telemedicine and mobile health apps, is transforming the pharmaceutical market in Estonia. Digital tools are increasingly integrated with treatments, enhancing patient engagement and driving innovation in drug delivery and disease management.

Growing Biosimilars Adoption to Boost Estonia Pharmaceutical Market Demand

The market is witnessing the rise of biosimilars as an alternative to biologic treatments. This trend is driving the market value upwards by increasing affordability and expanding treatment options, as well as attracting investments in biosimilar production.

Estonia Pharmaceutical Market Segmentation

The market report offers a detailed analysis of the market based on the following segments:

Market Breakup by Molecules Type

- Biologics & Biosimilars (Large Molecules)

??- Monoclonal Antibodies

??- Vaccines

??- Cell & Gene Therapy

??- Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Conventional Drugs (Small Molecules)

Market Breakup by Type

- Branded
- Generic

Market Breakup by Sales Channel

- Prescription
- OTC

Market Breakup by Indication

- Cardiovascular diseases
- Cancer
- Diabetes
- Infectious diseases
- Neurological disorders
- Respiratory diseases
- Autoimmune diseases
- Mental health disorders
- Gastrointestinal disorders
- Women's Health Diseases
- Genetic and Rare genetic diseases
- Dermatological conditions
- Obesity
- Renal diseases
- Liver conditions
- Hematological disorders
- Eye conditions
- Infertility conditions
- Endocrine disorders
- Allergies
- Others

Market Breakup by Route of Administration

- Oral
- Topical
- Parenteral
- Inhalation
- Others

Market Breakup by?Formulation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Tablet
- Capsules
- Injectable
- Sprays
- Suspensions
- Powders
- Other Formulations

Market Breakup by?Age Group

- Children & Adolescents
- Adults
- Geriatric

Market Breakup?End User

- Hospitals
- Clinics
- Others

Estonia Pharmaceutical Market Share

Market Segmentation Based on Indication to Witness Growth

Based on indication, the infectious disease category is expected to hold a significant share in the Estonia pharmaceutical market due to the country's ongoing efforts to combat various infectious diseases, including bacterial, viral, and fungal infections. The increasing prevalence of infections, along with growing awareness and the adoption of advanced treatments, drives this segment's dominance. Additionally, government initiatives and collaborations with global pharmaceutical companies contribute to the continuous expansion of this category in Estonia's healthcare landscape.

Estonia Pharmaceutical Market Analysis by Region

Estonia's strategic location in Northern Europe enhances trade opportunities, while its focus on innovation fosters pharmaceutical research and development. Strong government support for healthcare initiatives and streamlined approval processes attract international investments. Additionally, Estonia's high adoption of technology ensures accessibility and cost-effective drug distribution, positioning the market as a leader in delivering modern, patient-centric pharmaceutical solutions.

Leading Players in the Estonia Pharmaceutical Market

The key features of the market report comprise patent analysis, clinical trials analysis, grants analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:

AbbVie Inc.

AbbVie, founded in 2013 and headquartered in North Chicago, Illinois, focuses on immunology, oncology, neuroscience, and virology. It is known for its blockbuster drug, Humira, and continues to lead innovations in biologics and biosimilars.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Merck & Co., Inc.

Established in 1891 and headquartered in Kenilworth, New Jersey, Merck is a global leader in pharmaceuticals, vaccines, and animal health. Its oncology drug Keytruda and other vaccines and treatments play a significant role in the market.

Novartis AG

Headquartered in Basel, Switzerland, and founded in 1996, Novartis specialises in prescription medicines, particularly in areas such as oncology, cardiology, and ophthalmology. It develops innovative treatments and has a strong pipeline of digital health solutions.

Pfizer Inc.

Pfizer, based in New York, was founded in 1849 and is a leading biopharmaceutical company. It is well-known for its vaccines, including the COVID-19 vaccine, and its treatments across oncology, immunology, and rare diseases.

Other key players in the market include Sanofi SA, F. Hoffmann-La Roche AG, AstraZeneca plc, Eli Lilly and Company, and GSK plc.

Key Questions Answered in the Estonia Pharmaceutical Market

- What was the Estonia pharmaceutical market value in 2024?
- What is the Estonia pharmaceutical market forecast outlook for 2025-2034?
- What is the market breakup based on the molecules type?
- What is the market breakup based on the type?
- What is the market segmentation based on the sales channel?
- What is the market breakup based on the indication?
- What is the market segmentation based on the route of administration?
- What is the market breakup based on the age group?
- What is the market breakup based on the end user?
- What is the market breakup based on the formulation?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- Which country is expected to experience expedited growth during the forecast period?
- What are the major Estonia pharmaceutical market trends?
- Which indication will lead the market segment?
- Which sales channel will lead the market segment?
- Who are the key players involved in the Estonia pharmaceutical market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

Table of Contents:

- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.3 Report Coverage - Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Estonia Pharmaceutical Market Overview
 - 3.1 Europe Pharmaceutical Market
 - 3.1.1 Europe Pharmaceutical Market Historical Value (2018-2024)
 - 3.1.2 Europe Pharmaceutical Market Forecast Value (2025-2034)
 - 3.2 Estonia Pharmaceutical Market Overview
 - 3.2.1 Estonia Pharmaceutical Market Historical Value (2018-2024)
 - 3.2.2 Estonia Pharmaceutical Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
 - 4.1 Key Vendors
 - 4.2 Prospective Leaders
 - 4.3 Niche Leaders
 - 4.4 Disruptors
- 5 Estonia Pharmaceutical Market Landscape*
 - 5.1 Estonia Pharmaceutical Market: Developers Landscape
 - 5.1.1 Analysis by Year of Establishment
 - 5.1.2 Analysis by Company Size
 - 5.1.3 Analysis by Region
 - 5.2 Estonia Pharmaceutical Market: Product Landscape
 - 5.2.1 Analysis by Molecules Type
 - 5.2.2 Analysis by Type
 - 5.2.3 Analysis by Indication
 - 5.2.4 Analysis by Formulation
 - 5.2.5 Analysis by Route of Administration
- 6 Estonia Pharmaceutical Market Dynamics
 - 6.1 Market Drivers and Constraints
 - 6.2 SWOT Analysis
 - 6.2.1 Strengths
 - 6.2.2 Weaknesses
 - 6.2.3 Opportunities
 - 6.2.4 Threats
 - 6.3 PESTEL Analysis
 - 6.3.1 Political
 - 6.3.2 Economic
 - 6.3.3 Social
 - 6.3.4 Technological
 - 6.3.5 Legal
 - 6.3.6 Environment
 - 6.4 Porter's Five Forces Model
 - 6.4.1 Bargaining Power of Suppliers
 - 6.4.2 Bargaining Power of Buyers
 - 6.4.3 Threat of New Entrants
 - 6.4.4 Threat of Substitutes
 - 6.4.5 Degree of Rivalry
 - 6.5 Key Demand Indicators

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Estonia Pharmaceutical Market Segmentation (218-2034)
 - 7.1 Estonia Pharmaceutical Market (2018-2034) by Molecules Type
 - 7.1.1 Market Overview
 - 7.1.2 Biologics & Biosimilars (Large Molecules)
 - 7.1.2.1 Monoclonal Antibodies
 - 7.1.2.2 Vaccines
 - 7.1.2.3 Cell & Gene Therapy
 - 7.1.2.4 Others
 - 7.1.3 Conventional Drugs (Small Molecules)
 - 7.2 Estonia Pharmaceutical Market (2018-2034) by Type
 - 7.2.1 Market Overview
 - 7.2.2 Branded
 - 7.2.3 Generic
 - 7.3 Estonia Pharmaceutical Market (2018-2034) by Sales Channel
 - 7.3.1 Market Overview
 - 7.3.2 Prescription
 - 7.3.3 OTC
 - 7.4 Estonia Pharmaceutical Market (2018-2034) by Indication
 - 7.4.1 Market Overview
 - 7.4.2 Cardiovascular diseases
 - 7.4.3 Cancer
 - 7.4.4 Diabetes
 - 7.4.5 Infectious diseases
 - 7.4.6 Neurological disorders
 - 7.4.7 Respiratory diseases
 - 7.4.8 Autoimmune diseases
 - 7.4.9 Mental health disorders
 - 7.4.10 Gastrointestinal disorders
 - 7.4.11 Women's Health Diseases
 - 7.4.12 Genetic and Rare genetic diseases
 - 7.4.13 Dermatological conditions
 - 7.4.14 Obesity
 - 7.4.15 Renal diseases
 - 7.4.16 Liver conditions
 - 7.4.17 Hematological disorders
 - 7.4.18 Eye conditions
 - 7.4.19 Infertility conditions
 - 7.4.20 Endocrine disorders
 - 7.4.21 Allergies
 - 7.4.22 Others
 - 7.5 Estonia Pharmaceutical Market (2018-2034) by Route of Administration
 - 7.5.1 Market Overview
 - 7.5.2 Oral
 - 7.5.3 Topical

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.5.4 Parenteral
- 7.5.5 Inhalation
- 7.5.6 Others
- 7.6 Estonia Pharmaceutical Market (2018-2034) by Formulation
 - 7.6.1 Market Overview
 - 7.6.2 Tablet
 - 7.6.3 Capsules
 - 7.6.4 Injectable
 - 7.6.5 Sprays
 - 7.6.6 Suspensions
 - 7.6.7 Powders
 - 7.6.8 Other Formulations
- 7.7 Estonia Pharmaceutical Market (2018-2034) by Age Group
 - 7.7.1 Market Overview
 - 7.7.2 Children & Adolescents
 - 7.7.3 Adults
 - 7.7.4 Geriatric
- 7.8 Estonia Pharmaceutical Market (2018-2034) by End User
 - 7.8.1 Market Overview
 - 7.8.2 Hospitals
 - 7.8.3 Clinics
 - 7.8.4 Others
- 8 Regulatory Framework
- 9 Patent Analysis
 - 9.1 Analysis by Type of Patent
 - 9.2 Analysis by Publication Year
 - 9.3 Analysis by Issuing Authority
 - 9.4 Analysis by Patent Age
 - 9.5 Analysis by CPC Analysis
 - 9.6 Analysis by Patent Valuation
- 10 Clinical Trial Analysis
 - 10.1 Analysis by Trial Registration Year
 - 10.2 Analysis by Trial Status
 - 10.3 Analysis by Trial Phase
 - 10.4 Analysis by Therapeutic Area
 - 10.5 Analysis by Geography
- 11 Grant Analysis
 - 11.1 Analysis by Year
 - 11.2 Analysis by Amount Awarded
 - 11.3 Analysis by Issuing Authority
 - 11.4 Analysis by Grant Product
 - 11.5 Analysis by Funding Institute
 - 11.6 Analysis by Departments
 - 11.7 Analysis by Recipient Organization
- 12 Funding and Investment Analysis
 - 12.1 Analysis by Funding Instances
 - 12.2 Analysis by Drug Class of Funding

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.3 Analysis by Funding Amount
- 12.4 Analysis by Leading Players
- 12.5 Analysis by Leading Investors
- 12.6 Analysis by Geography
- 13 Strategic Initiatives
 - 13.1 Analysis by Partnership Instances
 - 13.2 Analysis by Drug Class of Partnership
 - 13.3 Analysis by Leading Players
 - 13.4 Analysis by Geography
- 14 Supplier Landscape
 - 14.1 Market Share Analysis (Top 5 Companies)
 - 14.2 AbbVie Inc.
 - 14.2.1 Financial Analysis
 - 14.2.2 Product Portfolio
 - 14.2.3 Demographic Reach and Achievements
 - 14.2.4 Company News and Development
 - 14.2.5 Certifications
 - 14.3 Merck & Co., Inc
 - 14.3.1 Financial Analysis
 - 14.3.2 Product Portfolio
 - 14.3.3 Demographic Reach and Achievements
 - 14.3.4 Company News and Development
 - 14.3.5 Certifications
 - 14.4 Novartis AG
 - 14.4.1 Financial Analysis
 - 14.4.2 Product Portfolio
 - 14.4.3 Demographic Reach and Achievements
 - 14.4.4 Company News and Development
 - 14.4.5 Certifications
 - 14.5 Pfizer Inc.
 - 14.5.1 Financial Analysis
 - 14.5.2 Product Portfolio
 - 14.5.3 Demographic Reach and Achievements
 - 14.5.4 Company News and Development
 - 14.5.5 Certifications
 - 14.6 Sanofi SA
 - 14.6.1 Financial Analysis
 - 14.6.2 Product Portfolio
 - 14.6.3 Demographic Reach and Achievements
 - 14.6.4 Company News and Development
 - 14.6.5 Certifications
 - 14.7 F. Hoffmann-La Roche AG
 - 14.7.1 Financial Analysis
 - 14.7.2 Product Portfolio
 - 14.7.3 Demographic Reach and Achievements
 - 14.7.4 Company News and Development
 - 14.7.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.8 AstraZeneca plc
 - 14.8.1 Financial Analysis
 - 14.8.2 Product Portfolio
 - 14.8.3 Demographic Reach and Achievements
 - 14.8.4 Company News and Development
 - 14.8.5 Certifications
- 14.9 Eli Lilly and Company
 - 14.9.1 Financial Analysis
 - 14.9.2 Product Portfolio
 - 14.9.3 Demographic Reach and Achievements
 - 14.9.4 Company News and Development
 - 14.9.5 Certifications
- 14.10 GSK plc.
 - 14.10.1 Financial Analysis
 - 14.10.2 Product Portfolio
 - 14.10.3 Demographic Reach and Achievements
 - 14.10.4 Company News and Development
 - 14.10.5 Certifications
- 15 Estonia Pharmaceutical Market - Distribution Model (Additional Insight)
 - 15.1 Overview
 - 15.2 Potential Distributors
 - 15.3 Key Parameters for Distribution Partner Assessment
- 16 Key Opinion Leaders (KOL) Insights (Additional Insight)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Estonia Pharmaceutical Market Report and Forecast 2025-2034

Market Report | 2025-06-25 | 250 pages | EMR Inc.

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$2789.00
	Five User License	\$3909.00
	Corporate License	\$5099.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-23"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com